| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 9,884,104
- Publication Date: February 06, 2018
- Appl. No: 15/018857
- Application Filed: February 08, 2016
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services (Bethesda, MD, US)
- Claim: 1. An immunogenic composition comprising a La Crosse virus polypeptide or a nucleic acid molecule encoding same, wherein said La Crosse virus polypeptide comprises a mutation at amino acid 148 of G N .
- Claim: 2. The composition of claim 1 , wherein the mutated amino acid at position 148 of G N is Alanine.
- Claim: 3. The composition of claim 1 , wherein amino acid 148 of G N is deleted.
- Claim: 4. The composition of claim 1 , wherein the mutated amino acid at position 148 of G N is any amino acid other than Threonine.
- Claim: 5. The composition of claim 1 , wherein said LACV polypeptide is a LACV/human/1960 virus sequence, LACV/mosquito/1978 virus sequence, or a LACV/human/1978 virus sequence.
- Claim: 6. The composition of claim 5 , wherein said LACV polypeptide sequence has at least about 85%, 88%, 90%, 92%, 95%, 97%, 98%, 99%, or 99.9% amino acid identity to an amino acid sequence of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.
- Claim: 7. The composition of claim 1 , wherein said nucleic acid molecule is codon-optimized for expression in humans.
- Claim: 8. A method of inducing an immune response against an LACV infection in a mammal, comprising administering to said mammal a therapeutically effective amount of the composition of claim 1 .
- Claim: 9. A method of producing an immunogenic composition for inducing an immune response against an LACV, comprising the steps of providing the composition of claim 1 ; and formulating said composition for delivery to a human.
- Patent References Cited: 8298541 October 2012 Whitehead et al. ; 2014/0023679 January 2014 Whitehead et al. ; WO 2005/051313 June 2005
- Other References: Bennett et al. (Virology Journal. May 8, 2007; 4(1): 41). cited by examiner ; Putkuri et al. (Infection, Genetics, and Evolution. 2014; 22: 164-173). cited by examiner ; Elliott (Nature Reviews Microbiology. Oct. 2014; 12: 673-685). cited by examiner ; Schoen et al. (European Journal of Cell Biology. 2015; 94: 384-390). cited by examiner ; Bennett et al., “Genome Sequence Analysis of La Crosse Virus and in Vitro and in Vivo Phenotypes,” Virology Journal, 4:41, 2007. cited by applicant ; Bennett et al., “A Recombinant Chimeric La Crosse Virus Expressing the Surface Glycoproteins of Jamestown Canyon Virus is Immunogenic and Protective against Challenge with either Parental Virus in Mice or Monkeys,” Journal of Virology, vol. 86, No. 1, pp. 420-426, 2012. cited by applicant ; Blakqori et al., “Efficient cDNA-Based Rescue of La Crosse Bunyaviruses Expressing or Lacking the Nonstructural Protein NSs,” Journal of Virology, vol. 79, No. 16, pp. 10420-10428, 2005. cited by applicant ; Bridgen et al, “Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs,” PNAS, vol. 93, pp. 15400-15404, 1996. cited by applicant ; Cheng et al, “Potential for evolution of California serogroup bunyaviruses by genome reassortment in Aedes albopictus,” American Journal of Tropical Medicine and Hygiene, vol. 60, No. 3, pp. 430-438, 1999. cited by applicant ; Huang et al., “Comparison of the MRNA Genome Segments of Two Human Isolates of La Crosse Virus,” Virus Research, vol. 36, No. 2-3, pp. 177-185, 1995. cited by applicant ; Janssen et al, “Virulence of La Crosse virus is under polygenic control,” Journal of Virology, vol. 59, No. 1, pp. 1-7, 1986. cited by applicant ; Plassmeyer et al., “California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry,” Virology, vol. 338, pp. 121-132, 2005. cited by applicant ; Roberts et al., “Completion of the La Crosse Virus Genome Sequence and Genetic Comparisons of the L Proteins of the Bunyaviridae”, Virology, vol. 206, No. 1, pp. 742-745, 1995. cited by applicant ; Sidwell et al., “Viruses of the Bunya- and Togaviridae Families: Potential as Bioterrorism Agents and Means of Control,” Antiviral Research, vol. 57, No. 1-2, pp. 101-111, 2003. cited by applicant
- Primary Examiner: Foley, Shanon A.
- Attorney, Agent or Firm: Klarquist Sparkman, LLP
|
